Close Menu

NEW YORK – The US Food and Drug Administration has updated its requirements for molecular diagnostic developers seeking Emergency Use Authorization for COVID-19 tests to include the use of actual positive specimens.

In the eighth of its weekly virtual town hall meetings on Wednesday, Timothy Stenzel, director of the agency's office if in vitro diagnostics and radiological health, said going forward FDA will require developers to use such specimens as part of the validation process.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

According to CNBC, Pfizer has announced that its SARS-CoV-2 vaccine data won't be ready this week.

A number of United Nations agencies push for scientific findings to be made accessible through open science.

Paris-Saclay University garners international regard following a decade-long effort to establish the new research university, Nature News reports.

In Nucleic Acids Research this week: database to house IndiGen sequencing data, database of SARS-CoV-2 docking scores, and more.